Document is current
Any future updates will be listed below
-
Authors
Milani, Michela https://orcid.org/0000-0002-0363-678X
Canepari, Cesare
Assanelli, Simone
Merlin, Simone
Borroni, Ester
Starinieri, Francesco https://orcid.org/0000-0003-0502-4442
Biffi, Mauro https://orcid.org/0000-0002-6914-2854
Russo, Fabio
Fabiano, Anna
Zambroni, Desirèe https://orcid.org/0000-0003-4027-1094
Annoni, Andrea https://orcid.org/0000-0002-8541-2578
Naldini, Luigi https://orcid.org/0000-0002-7835-527X
Follenzi, Antonia
Cantore, Alessio https://orcid.org/0000-0002-9741-997X
-
Funding
Funding for this research was provided by:
Fondazione Telethon (SR-Tiget Core Grant TTACC0422TT)
European Commission (UPGRADE)
- License Information
-
More Information
Article History
Received: 6 September 2023
Revised: 15 April 2024
Accepted: 16 April 2024
First Online: 29 April 2024
Disclosure and competing interests statement
: LN, AC, AA, MM, AFo, and SM are inventors on patent applications submitted by Fondazione Telethon, San Raffaele Scientific Institute, Bioverativ/Sanofi or University of Piemonte Orientale on LV technology related to the work presented in this manuscript. Fondazione Telethon and San Raffaele Scientific Institute through SR-Tiget, have established a research collaboration on liver-directed lentiviral gene therapy of hemophilia with GeneSpire. Luigi Naldini is a member of the journal’s editorial board. This has no bearing on the editorial consideration of this article for publication. The remaining authors declare no competing interests.
